Investigational drug · Phase 2
TUB-040
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Non-small Cell Lung Cancer, Uterine Endometrial Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "TUB-040"
First trial start
2024
Jun 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TUB-040", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Non-small Cell Lung Cancer
- Uterine Endometrial Cancer
- NSCLC
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Endometrial cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "TUB-040" as an intervention, largest first.
Gilead SciencesGilead Sciences (GILD)
NCT06303505 · 334 participants (planned) · Start Jun 12, 2024 · Primary completion Dec 2027
Drug: TUB-040; Bevacizumab · For: Ovarian Cancer; Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Atlanta, Georgia; Boston, Massachusetts · 21 sites in all
- Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune TherapyNot yet recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07743541 · 100 participants (planned) · Start Oct 2026 · Primary completion Sep 2029
Drug: TUB-040 - Dose escalation; TUB-040 - RP2D · For: Uterine Endometrial Cancer
Sites: Los Angeles, California; East Brunswick, New Jersey; Lake Success, New York · 4 sites in all
- Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung CancerNot yet recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07806773 · 80 participants (planned) · Start Nov 2026 · Primary completion May 2029
Drug: TUB-040 · For: NSCLC; Non Small Cell Lung Cancer
Sites: Los Angeles, California; East Brunswick, New Jersey
Gilead SciencesGilead Sciences (GILD)
NCT07736937 · 72 participants (planned) · Start Mar 30, 2026 · Primary completion Mar 2028
Drug: TUB-040 + Carbo + BEV · For: Ovarian Cancer
Sites: Los Angeles, California; East Brunswick, New Jersey; New York, New York · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Has next-generation antibody-drug conjugate engineering finally unlocked NaPi2b in ovarian cancer?
de Mello Graziano L, Leis LV, Loureiro FA, et al. · Int J Gynecol Cancer 2026
- TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile.
Vogl AM, Schmitt S, Mai I, et al. · Mol Cancer Ther 2025
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.